Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
December 04 2008 - 8:00AM
PR Newswire (US)
NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH) today announced that Jonathan Lewis, M.D., Ph.D.,
has stepped down from his position as a director of the Company,
effective December 2, 2008. Dr. Lewis advised the Company that his
decision to leave the Delcath board is a result of additional
commitments to new leadership positions. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO) Dr.
Harold Koplewicz, Chairman of the Board of Directors of Delcath
Systems, commented, "We all thank Jon for his dedicated service to
Delcath and wish him the best in his future professional pursuits."
About Delcath Systems, Inc. Delcath Systems, Inc. is a medical
technology company specializing in cancer treatment. The Company is
testing a proprietary, patented drug delivery system for the
treatment of liver cancers. Delcath's novel drug delivery platform
is testing the delivery of ultra-high doses of anti-cancer drugs to
the liver while preventing these high doses of drug from entering
the patient's bloodstream. The Company is currently enrolling
patients in Phase III and Phase II clinical studies for the
treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight
patents on a worldwide basis including the U.S., Europe, Asia and
Canada. For more information, please visit the Company's website at
http://www.delcath.com/. This release contains express or implied
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are based on the
current belief of management. These statements relate to, among
other things, the results to date of our phase III clinical trials
as described above. These statements are neither promises nor
guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular,
the risks and uncertainties include, among other things: risks that
any results of any trials to date are interim and may not be borne
out or supported by subsequent or final results or that any such
trials may not be fully completed as necessary; risks relating to
our ability to further advance the development of the our system in
clinical trials; risks of any failure to comply with regulations
relating to our system, including FDA requirements; risks of
failure to obtain the financial resources to complete development
of our system; the risk that the FDA may interpret the results of
our studies differently from any interpretation we may have; and
all of the other risks discussed from time to time in our filings
with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO
http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc.
CONTACT: Richard L. Taney of Delcath Systems, Inc.,
+1-212-489-2100, ; or Robin Wagge of Rubenstein Associates, Inc.,
+1-212-843-8006, , for Delcath Systems, Inc. Web Site:
http://www.delcath.com/
Copyright